Melanotan II

Mechanism

Melanotan-II is a synthetic, cyclic analog of α-MSH, the endogenous melanocortin peptide that triggers melanogenesis (the production of melanin pigment) in skin. It binds primarily to the MC1R (melanocortin 1) receptor, driving the same cellular cascade as natural α-MSH but with much greater stability and potency.

It also binds MC3R and MC4R, which are expressed in the central nervous system and have roles in sexual function, appetite, and energy expenditure. The MC4R activity is the mechanism behind the well-known “side effect” of penile erection, which is significant enough that a structurally related compound (bremelanotide, PT-141) was specifically developed as a treatment for hypoactive sexual desire disorder.

The desired effect (tanning) and several of the adverse effects (sexual side effects, nausea, appetite suppression) all derive from the same mechanism. They are not separable.

What the evidence shows

Pharmacology and short-term efficacy:

The melanocortin pigmentation effect is well-characterized at the receptor level. Pilot studies from the 1990s and early 2000s demonstrated that subcutaneous administration produces measurable increases in skin pigmentation in humans. The effect is dose-dependent and reversible upon discontinuation.

Adverse event literature:

This is where the gap between popular discussion and the medical literature is widest. Published case reports and case series include:

• Priapism requiring emergency intervention — multiple case reports
• Severe nausea and vomiting — almost universal at the doses required for visible tanning effect
• Pre-existing nevi darkening and new atypical/dysplastic nevi — multiple case reports in dermatology journals; the causal mechanism (MC1R activation in existing melanocytic lesions) is biologically plausible
• A single case report of melanoma developing in a patient with prior MT-II use — causation not established, but the report is in the literature

The melanoma association is unproven but biologically plausible. MC1R signaling is involved in melanocyte proliferation; whether stimulating that pathway over months of use measurably affects long-term melanoma risk is not known and would be very hard to study prospectively.

Why no large trials:

Original commercial development by Competitive Technologies and Clinuvel pivoted away from cosmetic tanning to a related compound (afamelanotide, used in erythropoietic protoporphyria, where it is an approved orphan drug). Cosmetic tanning was abandoned as an indication; large RCTs in healthy volunteers were never conducted. The published evidence base will not grow significantly because no commercial sponsor is funding it.

Dosing literature

There is no approved or consensus dose. Recreational and gray-market protocols typically describe:

• Loading phase: 250–500 mcg/day subcutaneous for 1–4 weeks, until the desired pigmentation level is reached
• Maintenance: 500–1000 mcg per week, sometimes less, sometimes only during sun exposure

Higher doses produce faster tanning and worse adverse events. The titration discipline is real even though the use is cosmetic.

Risks and adverse events

Common (most users experience):
– Nausea, especially during the first 30–60 minutes after injection
– Facial flushing
– Reduced appetite
– Spontaneous erection in male users (often presented as a “feature” in marketing)

Uncommon but documented:
– Priapism — sustained erection requiring medical intervention; documented in case reports, can occur even at typical doses
– Severe vomiting — to the point of dehydration in some published cases
– Tachycardia and hypertension
– Hyperpigmentation of pre-existing nevi

Less common, more serious:
– Development of new atypical/dysplastic nevi during treatment
– Worsening of pre-existing dysplastic nevi
– Possible association with melanoma — reported in case literature; causation unproven

Self-sourced quality concerns:
– Mass-spectrometry analysis of “research peptide” MT-II samples has repeatedly found incorrect sequences, wrong concentrations, and bacterial contamination
– The same vial may not contain the same dose at week 12 as at week 1

Regulatory status

Notably: afamelanotide (Scenesse), a related but distinct molecule, is approved for erythropoietic protoporphyria (EPP). Afamelanotide is not Melanotan-II. They are sometimes confused; do not assume safety information about the approved product applies to the unapproved one.

Where to get it

We do not route readers to a fulfillment partner for Melanotan-II under any circumstance. The verdict (Cautionary) and the regulatory status combine to a no.

If you are using it anyway — and many readers will be, regardless of what we recommend — please:

1. Get a dermatologist’s mole map before you start. Photograph it. This is the single most important piece of harm reduction available for this peptide.
2. Stop and seek evaluation at the first sign of any new pigmented lesion or change in an existing one.
3. Use the lowest effective dose. The MC1R receptor saturates; higher doses do not produce more tanning, just more adverse events.
4. Avoid combining with sun-tanning bed use (which has its own well-characterized melanoma risk that may compound).

(See How we make money — the absence of a partner link is a deliberate signal.)

References (selected)

1. Hjuler KF, Lorentzen HF. Melanoma associated with the use of Melanotan-II. Dermatology 2014. PubMed
2. Cardones AR, Grichnik JM. α-Melanocyte–stimulating hormone-induced eruptive nevi. Arch Dermatol 2009.
3. Brennan R et al. The dermatologic adverse effects of Melanotan-II: a review. Dermatol Online J 2015.
4. MHRA Drug Safety Update — Melanotan-II warnings (multiple years).
5. Habbema L et al. Risks of unregulated use of α-melanocyte–stimulating hormone analogues. Int J Dermatol 2017.